Log In
Print this Print this

BreMel/TNF-a (scFvMel/TNF-a)

  Manage Alerts
Collapse Summary General Information
Company Targa Therapeutics Corp.
DescriptionMAb sfFv fragment-payload fusion protein
Molecular Target Tumor-associated gp240
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMelanoma
Indication DetailsTreat metastatic melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today